vs
CHART INDUSTRIES INC（GTLS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
CHART INDUSTRIES INC的季度营收约是Revvity的1.4倍（$1.1B vs $772.1M），Revvity净利率更高（12.7% vs 5.0%，领先7.8%），Revvity同比增速更快（5.9% vs -2.5%），Revvity自由现金流更多（$161.8M vs $66.2M），过去两年Revvity的营收复合增速更高（9.0% vs 6.6%）
Oricon Inc.成立于1999年，是日本知名音乐产业集团的控股主体，主营日本本土及西洋音乐相关的行业资讯与数据统计服务。其前身为小池宗光于1967年11月创立的Original Confidence公司，凭借权威音乐排行榜广为人知，2002年4月正式承接原公司旗下的Oricon唱片排行榜业务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GTLS vs RVTY — 直观对比
营收规模更大
GTLS
是对方的1.4倍
$772.1M
营收增速更快
RVTY
高出8.3%
-2.5%
净利率更高
RVTY
高出7.8%
5.0%
自由现金流更多
RVTY
多$95.6M
$66.2M
两年增速更快
RVTY
近两年复合增速
6.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $53.6M | $98.4M |
| 毛利率 | 33.3% | — |
| 营业利润率 | 11.6% | 14.5% |
| 净利率 | 5.0% | 12.7% |
| 营收同比 | -2.5% | 5.9% |
| 净利润同比 | -32.7% | 3.9% |
| 每股收益（稀释后） | $1.06 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GTLSRVTY
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $1.0B | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.0B | $691.7M | ||
| Q1 24 | $950.7M | $649.9M |
净利润GTLSRVTY
| Q4 25 | $53.6M | $98.4M | ||
| Q3 25 | $-138.5M | $46.7M | ||
| Q2 25 | $76.1M | $53.9M | ||
| Q1 25 | $49.5M | $42.2M | ||
| Q4 24 | $79.6M | $94.6M | ||
| Q3 24 | $69.0M | $94.4M | ||
| Q2 24 | $58.6M | $55.4M | ||
| Q1 24 | $11.3M | $26.0M |
毛利率GTLSRVTY
| Q4 25 | 33.3% | — | ||
| Q3 25 | 34.1% | 53.6% | ||
| Q2 25 | 33.6% | 54.5% | ||
| Q1 25 | 33.9% | 56.5% | ||
| Q4 24 | 33.6% | — | ||
| Q3 24 | 34.1% | 56.3% | ||
| Q2 24 | 33.8% | 55.7% | ||
| Q1 24 | 31.8% | 54.6% |
营业利润率GTLSRVTY
| Q4 25 | 11.6% | 14.5% | ||
| Q3 25 | -8.0% | 11.7% | ||
| Q2 25 | 15.7% | 12.6% | ||
| Q1 25 | 15.2% | 10.9% | ||
| Q4 24 | 17.0% | 16.3% | ||
| Q3 24 | 16.8% | 14.3% | ||
| Q2 24 | 16.1% | 12.4% | ||
| Q1 24 | 11.9% | 6.8% |
净利率GTLSRVTY
| Q4 25 | 5.0% | 12.7% | ||
| Q3 25 | -12.6% | 6.7% | ||
| Q2 25 | 7.0% | 7.5% | ||
| Q1 25 | 4.9% | 6.4% | ||
| Q4 24 | 7.2% | 13.0% | ||
| Q3 24 | 6.5% | 13.8% | ||
| Q2 24 | 5.6% | 8.0% | ||
| Q1 24 | 1.2% | 4.0% |
每股收益（稀释后）GTLSRVTY
| Q4 25 | $1.06 | $0.86 | ||
| Q3 25 | $-3.23 | $0.40 | ||
| Q2 25 | $1.53 | $0.46 | ||
| Q1 25 | $0.94 | $0.35 | ||
| Q4 24 | $1.57 | $0.77 | ||
| Q3 24 | $1.33 | $0.77 | ||
| Q2 24 | $1.10 | $0.45 | ||
| Q1 24 | $0.10 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $366.0M | $919.9M |
| 总债务越低越好 | $3.7B | — |
| 股东权益账面价值 | $3.2B | $7.3B |
| 总资产 | $9.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.13× | — |
8季度趋势，按日历期对齐
现金及短期投资GTLSRVTY
| Q4 25 | $366.0M | $919.9M | ||
| Q3 25 | $399.2M | $931.4M | ||
| Q2 25 | $342.3M | $991.8M | ||
| Q1 25 | $296.2M | $1.1B | ||
| Q4 24 | $308.6M | $1.2B | ||
| Q3 24 | $310.2M | $1.2B | ||
| Q2 24 | $247.4M | $2.0B | ||
| Q1 24 | $191.9M | $1.7B |
总债务GTLSRVTY
| Q4 25 | $3.7B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $3.8B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GTLSRVTY
| Q4 25 | $3.2B | $7.3B | ||
| Q3 25 | $3.2B | $7.4B | ||
| Q2 25 | $3.4B | $7.6B | ||
| Q1 25 | $3.0B | $7.6B | ||
| Q4 24 | $2.8B | $7.7B | ||
| Q3 24 | $3.0B | $7.9B | ||
| Q2 24 | $2.7B | $7.9B | ||
| Q1 24 | $2.7B | $7.8B |
总资产GTLSRVTY
| Q4 25 | $9.8B | $12.2B | ||
| Q3 25 | $9.8B | $12.1B | ||
| Q2 25 | $9.7B | $12.4B | ||
| Q1 25 | $9.3B | $12.4B | ||
| Q4 24 | $9.1B | $12.4B | ||
| Q3 24 | $9.5B | $12.8B | ||
| Q2 24 | $9.3B | $13.4B | ||
| Q1 24 | $9.2B | $13.4B |
负债/权益比GTLSRVTY
| Q4 25 | 1.13× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $88.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $66.2M | $161.8M |
| 自由现金流率自由现金流/营收 | 6.1% | 21.0% |
| 资本支出强度资本支出/营收 | 2.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.66× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $202.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流GTLSRVTY
| Q4 25 | $88.8M | $182.0M | ||
| Q3 25 | $118.0M | $138.5M | ||
| Q2 25 | $145.9M | $134.3M | ||
| Q1 25 | $-60.0M | $128.2M | ||
| Q4 24 | $281.4M | $174.2M | ||
| Q3 24 | $200.6M | $147.9M | ||
| Q2 24 | $116.1M | $158.6M | ||
| Q1 24 | $-95.1M | $147.6M |
自由现金流GTLSRVTY
| Q4 25 | $66.2M | $161.8M | ||
| Q3 25 | $94.7M | $120.0M | ||
| Q2 25 | $122.0M | $115.5M | ||
| Q1 25 | $-80.1M | $112.2M | ||
| Q4 24 | $260.9M | $149.8M | ||
| Q3 24 | $174.5M | $125.6M | ||
| Q2 24 | $88.0M | $136.6M | ||
| Q1 24 | $-141.2M | $129.7M |
自由现金流率GTLSRVTY
| Q4 25 | 6.1% | 21.0% | ||
| Q3 25 | 8.6% | 17.2% | ||
| Q2 25 | 11.3% | 16.0% | ||
| Q1 25 | -8.0% | 16.9% | ||
| Q4 24 | 23.6% | 20.5% | ||
| Q3 24 | 16.4% | 18.4% | ||
| Q2 24 | 8.5% | 19.7% | ||
| Q1 24 | -14.9% | 20.0% |
资本支出强度GTLSRVTY
| Q4 25 | 2.1% | 2.6% | ||
| Q3 25 | 2.1% | 2.6% | ||
| Q2 25 | 2.2% | 2.6% | ||
| Q1 25 | 2.0% | 2.4% | ||
| Q4 24 | 1.9% | 3.4% | ||
| Q3 24 | 2.5% | 3.3% | ||
| Q2 24 | 2.7% | 3.2% | ||
| Q1 24 | 4.8% | 2.7% |
现金转化率GTLSRVTY
| Q4 25 | 1.66× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 1.92× | 2.49× | ||
| Q1 25 | -1.21× | 3.03× | ||
| Q4 24 | 3.54× | 1.84× | ||
| Q3 24 | 2.91× | 1.57× | ||
| Q2 24 | 1.98× | 2.87× | ||
| Q1 24 | -8.42× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GTLS
| Repair Service And Leasing Segment | $330.4M | 31% |
| Heat Transfer Systems Segment | $325.8M | 30% |
| Specialty Products Segment | $259.5M | 24% |
| Transferred Over Time | $94.4M | 9% |
| Transferred At Point In Time | $69.5M | 6% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
